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Figure S1. Splicing effect of control ASO, therapeutic ASO-10-27, or ASO-20-37. (A) ICV injection 
of 100 g or IP injection of 200 mg/kg/d control ASO did not affect SMN2 splicing in spinal cord or 
liver, respectively, analyzed at PS7 or PS14 (n = 3). (B) Time-course analysis of the effect of ICV 
injection of 100 g ASO-10-27 on SMN2 splicing in spinal cord (n = 3). (C) Compared with PS7, 10 
g or 25 g ASO-20-37 further inhibited exon 7 inclusion at PS30 in a dose-dependent manner (n = 3). 
25 g ASO has a stronger effect than 10 g. (D) Similar splicing effect in PS7 spinal cord between 
ICV injection of 25 µg ASO-20-37 with or without additional IP injection of 200 mg/kg/d ASO-20-37 
(n = 3). FL, 7, and 5+ 7: full-length, exon-7-skipped transcripts, and mRNA lacking both exon 5 
and exon 7, respectively. S: 5 l saline, C: 100 g control ASO; 25+IP: combination of ICV injection 
of 25 µg and IP injection of 200 mg/kg/d ASO-20-37.!
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Figure S2. ASO uptake in tissues 7 days (A) or 30 days (B) after ICV injection of 100 g ASO-20-37 
(IHC). ASO is broadly detected in CNS cells, and mainly in liver sinusoids. ASO is only weakly 
detectable in heart, lung, and quadriceps muscle. Compared with PS7, PS30 uptake declines in the 
CNS. The brain and spinal cord regions indicated by open circles are also displayed at higher 
magnification in the insets. Scale bar: 1,000 and 200 m for 6  and 40  magnification. Saline: ICV 
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Figure S3. Phenotypic effect of ASO-20-37. (A) Mice that receive ICV injection of 25 g ASO-20-37 
are smaller and show kyphosis. (B) Mice begin to lose body weight around 20 days after IP injection of 
200 mg/kg/d ASO-20-37. Control mice (n = 10) and mice injected with ASO-20-37 (n = 12) were 
analyzed. (C) IP injection of ASO-20-37 had no effect on motor function, analyzed by grip strength (n 
= 7. n.s., P = 0.9122) and rotarod task (n = 7. n.s., P = 0.3599) measured at PS21. (D) ICV injection of 
10 g ASO-20-37 had no effect on motor function, analyzed by grip strength (n = 3. n.s., P = 0.6601) 
and rotarod task (n = 3. n.s., P = 0.4227) measured at PS120. Control: ICV injection of 100 g control 



















Figure S4. Muscle histology. No overt muscle pathology in quadriceps (top) or tibialis anterior 
(bottom) is seen at end-stage PS70 in the mice given ICV injection of 25 g ASO-20-37. H&E, acetate 
non-specific esterase, and NADH dehydrogenase staining. Scale bar: 200 m. 
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PS30, +PS14/15 IP therapy
Figure S5. Amelioration by systemically administered therapeutic ASO. 200 mg/kg/d therapeutic ASO-10-
27 was injected intraperitoneally 14 and 15 days after IP injection of 200 mg/kg/d ASO-20-37. (A) 
Extended survival by ASO-10-27. Control mice (n = 10), mice without therapy (n = 15), and with IP 
injection of ASO-10-27 (n = 10) were analyzed. (B) Retained body weight. Control mice (n = 10), mice 
without therapy (n = 12), and with IP injection of ASO-10-27 (n = 10) were analyzed. The median survival 
days after the first injection of ASO-20-37 are given in parentheses for each group. (C) Increased exon 7 
inclusion in SMN2 in P30 liver (n = 3). (D) Ameliorated histological change in liver at PS30. There was 
only mild hepatocellular necrosis with sporadic enlarged cells (arrow), and inflammatory cell infiltration 
(arrowhead), particularly neutrophils. H&E staining. Scale bar: 200 m. (E) Retained serum AST and ALT 
levels (n = 5. n.s., P = 0.7732 and 0.4442, respectively) and IGF1 levels (n = 5. n.s., P = 0.1472). (F) 
Retained mRNA levels of hepatic Igf1 and Igfals at PS30 (n = 3). For Igfals in the mice treated with ASO-
20-37 only, the lower band in each doublet was quantitated. IP control or IP200 ASO-20-37: IP injection of 
200 mg/kg/d control ASO or ASO-20-37 for 2 days, respectively; +PS14/15 IP therapy: IP injection of 200 
mg/kg/d ASO-20-37 for 2 days and IP injections of 200 mg/kg/d ASO-10-27 at PS14 and PS15. We 
analyzed data using two-tailed t-tests, except for the logrank test for survival analysis. 
 Table S1. Sequences of the uniform 2’-MOE ASOs with phosphorothioate backbone and 5-methyl 
cytosines used in this study. 
Antisense oligonucleotide Sequence 
Control ASO 5´-TCATTTGCTTCATACAGG-3´ 
ASO-20-37 5´-GTGAGCACCTTCCTTCTT-3´ 
ASO-10-27 5´-TCACTTTCATAATGCTGG-3´ 
 Table S2. Echocardiographic measurements before and 25 days after IP injection of control ASO or ASO-
20-37. 
Female  IP control (n = 3) IP (n = 5) 
  Pre-surgery PS25 Pre-surgery PS25 
 Units Average SD Average SD Average SD Average SD 
HR b/min 540 32 486 2 513 16 459 23 
IVS; d mm 0.12 0.02 0.15 0.02 0.12 0.02 0.18 0.03 
LVID; d mm 3.52 0.07 3.78 0.18 3.60 0.09 3.21 0.14 
LVPW; d mm 0.81 0.06 0.99 0.08 0.82 0.06 1.03 0.10 
IVS; s mm 0.11 0.02 0.16 0.03 0.11 0.02 0.21 0.03 
LVID; s mm 2.01 0.07 1.97 0.23 2.09 0.10 1.76 0.17 
LVPW; s mm 1.24 0.08 1.44 0.12 1.24 0.07 1.47 0.10 
LV Vol; d µl 51.67 2.37 61.83 6.71 54.17 3.44 42.29 4.62 
LV Vol; s µl 13.00 1.20 12.89 3.54 14.38 1.74 9.69 2.32 
% EF % 75.00 2.28 79.81 4.07 73.79 2.31 77.43 4.50 
% FS % 43.01 2.09 48.06 4.08 41.98 2.03 45.16 4.14 
LV Mass mg 47.65 4.13 68.92 5.93 49.51 4.61 55.64 6.34 
 
Male  IP control (n = 3) IP (n = 5) 
  Pre-surgery PS25 Pre-surgery PS25 
 Units Average SD Average SD Average SD Average SD 
HR b/min 548 43 474 10 541 29 452 32 
IVS; d mm 0.11 0.02 0.14 0.02 0.11 0.02 0.47 0.04 
LVID; d mm 3.70 0.09 3.75 0.14 3.63 0.07 2.85 0.14 
LVPW; d mm 0.86 0.07 0.92 0.05 0.84 0.05 1.08 0.09 
IVS; s mm 0.11 0.02 0.14 0.03 0.12 0.02 0.55 0.04 
LVID; s mm 2.11 0.08 2.17 0.16 2.14 0.08 1.56 0.11 
LVPW; s mm 1.32 0.05 1.41 0.06 1.28 0.05 1.48 0.07 
LV Vol; d µl 58.07 3.30 60.42 5.34 55.59 2.56 32.21 3.57 
LV Vol; s µl 14.75 1.65 15.81 2.79 15.18 1.28 7.27 1.26 
% EF % 74.84 2.17 74.09 3.23 73.96 2.13 78.22 2.89 
% FS % 43.06 1.84 42.39 2.82 41.49 1.87 45.72 2.78 
LV Mass mg 54.30 4.62 61.74 5.17 50.73 3.82 65.04 19.16 
 
HR, heart rate; IVS, interventricular septum; LVID, left ventricular end-diastolic internal dimension; 
LVPW, left ventricular posterior wall; % EF, ejection fraction: % of (end-diastolic volume - end-systolic 
volume) / end-diastolic volume; % FS, fractional shortening: % of (end-diastolic dimension - end-systolic 
dimension) / end-diastolic dimension; d / s, systolic / diastolic; Vol, volume. 
IP control, 2-day IP injection of 200 mg/kg/d control ASO; IP, 2-day IP injection of 200 mg/kg/d ASO-20-
37. 
